Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Meddenovo Drug Design
Meddenovo is a drug design company specializing in AI-supported cyclic peptide therapeutics. Founded by academics with over 10 years of experience in drug design and biomolecular modeling, Meddenovo…
Meddenovo Drug Design
Meddenovo is a drug design company specializing in AI-supported cyclic peptide therapeutics. Founded by academics with over 10 years of experience in drug design and biomolecular modeling, Meddenovo…
TL;DR
Location: Lyon / Villeurbanne, France
Focus: AI-supported computational design of cyclic peptide therapeutics
Products: Mexa Screen (in-silico screening), Mexa Design (de-novo peptide design)
Founders: Dr. Ilke Ugur Marion; Dr. Antoine Marion
Funding: Pre-seed first closing (ACT Venture Partners); Seed round (Invest 101)
Company Overview
Problem Domain
Drug discovery and computational chemistry focused on cyclic peptide therapeutics targeting diseases with unmet medical needs.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
up to €1,000,000 (first closing announced)
Company announced first closing of pre-seed; described on company site
1,082,385 USD (total funding recorded)
Crunchbase records a Seed round announced Jan 1, 2025 listing Invest 101
Investor Signal
“ACT Venture Partners led pre-seed first closing; Invest 101 participated in a Seed round”